文献速递浆细胞疾病

意义未明单克隆丙种球蛋白病或冒烟型多发性骨髓瘤患者的个体化进展预测(PANGEA):一项回顾性多队列研究

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
PubMed 文献 · Lancet Haematol · 2023-01-01

这项回顾性多队列研究纳入6441例意义未明单克隆丙种球蛋白病或冒烟型多发性骨髓瘤患者,开发并验证了利用可及、随时间变化的生物标志物(M蛋白、游离轻链比值、年龄、肌酐、骨髓浆细胞比例及血红蛋白轨迹)预测进展至多发性骨髓瘤的PANGEA模型(含骨髓和不含骨髓数据),在验证队列中其预测准确性优于现行20/2/20和IMWG模型。

要点

  • PANGEA模型利用可及、随时间变化的生物标志物预测进展至多发性骨髓瘤。
  • 在验证队列1中,PANGEA模型(含骨髓)预测冒烟型多发性骨髓瘤进展的C统计量在首次就诊时从0.533升至0.756。
  • 在验证队列2中,PANGEA模型(含骨髓)预测意义未明单克隆丙种球蛋白病进展的C统计量在首次就诊时从0.640升至0.729。

核心结论

  • 在临床实践中使用PANGEA模型可使前驱疾病患者获得更准确的进展至多发性骨髓瘤的风险评估,从而促成更合适的治疗策略。

研究设计与样本

  • 回顾性、多队列研究,纳入6441例18岁及以上意义未明单克隆丙种球蛋白病或冒烟型多发性骨髓瘤患者,其中4931例(77%)为意义未明单克隆丙种球蛋白病,1510例(23%)为冒烟型多发性骨髓瘤,3430例(53%)为女性。
  • 使用来自Dana-Farber癌症研究所(美国波士顿;2019年11月13日至2022年4月13日标注)的训练队列评估多种建模方法并创建PANGEA模型。
  • PANGEA模型使用生物标志物(单克隆蛋白浓度、游离轻链比值、年龄、肌酐浓度和骨髓浆细胞百分比)及病历中的血红蛋白轨迹预测从前驱疾病进展至多发性骨髓瘤。
  • 模型在两个独立验证队列中验证:验证队列1来自National and Kapodistrian University of Athens(希腊雅典;2020年1月26日至2022年2月7日)和University College London(英国伦敦;2020年6月9日至2022年4月10日);验证队列2来自Registry of Monoclonal Gammopathies(捷克共和国;2004年1月5日至2022年3月10日)。
  • 比较PANGEA模型(含骨髓数据和不含骨髓数据)与现行标准(IMWG意义未明单克隆丙种球蛋白病标准和20/2/20冒烟型多发性骨髓瘤风险标准)。

主要发现

  • 在验证队列1中,与20/2/20模型相比,PANGEA模型(含骨髓)改善了对冒烟型多发性骨髓瘤进展至多发性骨髓瘤的预测,C统计量在患者首次就诊时从0.533(0.480-0.709)升至0.756(0.629-0.785),第二次就诊时从0.613(0.504-0.704)升至0.720(0.592-0.775),第三次就诊时从0.637(0.386-0.841)升至0.756(0.547-0.830)。
  • 在验证队列1中,与20/2/20模型相比,PANGEA模型(不含骨髓)改善了对冒烟型多发性骨髓瘤进展至多发性骨髓瘤的预测,C统计量在首次就诊时从0.534(0.501-0.672)升至0.692(0.614-0.736),第二次就诊时从0.573(0.518-0.647)升至0.693(0.605-0.734),第三次就诊时从0.560(0.497-0.645)升至0.692(0.570-0.708)。
  • 在验证队列2中,与IMWG滚动模型相比,PANGEA模型改善了对意义未明单克隆丙种球蛋白病进展至多发性骨髓瘤的预测,在首次就诊时PANGEA模型(含骨髓)的C统计量从0.640(0.518-0.718)升至0.729(0.643-0.941),PANGEA模型(不含骨髓)从0.670(0.523-0.729)升至0.879(0.586-0.938)。

关键数值与推荐

  • PANGEA模型(含骨髓)预测冒烟型多发性骨髓瘤进展的C统计量在验证队列1首次就诊时为0.756(0.629-0.785),第二次就诊时为0.720(0.592-0.775),第三次就诊时为0.756(0.547-0.830);20/2/20模型对应分别为0.533(0.480-0.709)、0.613(0.504-0.704)、0.637(0.386-0.841)。
  • PANGEA模型(不含骨髓)预测冒烟型多发性骨髓瘤进展的C统计量在验证队列1首次就诊时为0.692(0.614-0.736),第二次就诊时为0.693(0.605-0.734),第三次就诊时为0.692(0.570-0.708);20/2/20模型对应分别为0.534(0.501-0.672)、0.573(0.518-0.647)、0.560(0.497-0.645)。
  • 在验证队列2首次就诊时,PANGEA模型(含骨髓)预测意义未明单克隆丙种球蛋白病进展的C统计量为0.729(0.643-0.941),IMWG滚动模型为0.640(0.518-0.718);PANGEA模型(不含骨髓)为0.879(0.586-0.938),IMWG滚动模型为0.670(0.523-0.729)。

临床怎么用

  • 作者认为,在临床实践中使用PANGEA模型可使前驱疾病患者获得更准确的进展至多发性骨髓瘤的风险评估,从而促成更合适的治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with precursors to multiple myeloma are dichotomised as having monoclonal gammopathy of undetermined significance or smouldering multiple myeloma on the basis of monoclonal protein concentrations or bone marrow plasma cell percentage. Current risk stratifications use laboratory measurements at diagnosis and do not incorporate time-varying biomarkers. Our goal was to develop a monoclonal gammopathy of undetermined significance and smouldering multiple myeloma stratification algorithm that utilised accessible, time-varying biomarkers to model risk of progression to multiple myeloma. METHODS: In this retrospective, multicohort study, we included patients who were 18 years or older with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma. We evaluated several modelling approaches for predicting disease progression to multiple myeloma using a training cohort (with patients at Dana-Farber Cancer Institute, Boston, MA, USA; annotated from Nov, 13, 2019, to April, 13, 2022). We created the PANGEA models, which used data on biomarkers (monoclonal protein concentration, free light chain ratio, age, creatinine concentration, and bone marrow plasma cell percentage) and haemoglobin trajectories from medical records to predict progression from precursor disease to multiple myeloma. The models were validated in two independent validation cohorts from National and Kapodistrian University of Athens (Athens, Greece; from Jan 26, 2020, to Feb 7, 2022; validation cohort 1), University College London (London, UK; from June 9, 2020, to April 10, 2022; validation cohort 1), and Registry of Monoclonal Gammopathies (Czech Republic, Czech Republic; Jan 5, 2004, to March 10, 2022; validation cohort 2). We compared the PANGEA models (with bone marrow [BM] data and without bone marrow [no BM] data) to current criteria (International Myeloma Working Group [IMWG] monoclonal gammopathy of undetermined significance and 20/2/20 smouldering multiple myeloma risk criteria). FINDINGS: We included 6441 patients, 4931 (77%) with monoclonal gammopathy of undetermined significance and 1510 (23%) with smouldering multiple myeloma. 3430 (53%) of 6441 participants were female. The PANGEA model (BM) improved prediction of progression from smouldering multiple myeloma to multiple myeloma compared with the 20/2/20 model, with a C-statistic increase from 0·533 (0·480-0·709) to 0·756 (0·629-0·785) at patient visit 1 to the clinic, 0·613 (0·504-0·704) to 0·720 (0·592-0·775) at visit 2, and 0·637 (0·386-0·841) to 0·756 (0·547-0·830) at visit three in validation cohort 1. The PANGEA model (no BM) improved prediction of smouldering multiple myeloma progression to multiple myeloma compared with the 20/2/20 model with a C-statistic increase from 0·534 (0·501-0·672) to 0·692 (0·614-0·736) at visit 1, 0·573 (0·518-0·647) to 0·693 (0·605-0·734) at visit 2, and 0·560 (0·497-0·645) to 0·692 (0·570-0·708) at visit 3 in validation cohort 1. The PANGEA models improved prediction of monoclonal gammopathy of undetermined significance progression to multiple myeloma compared with the IMWG rolling model at visit 1 in validation cohort 2, with C-statistics increases from 0·640 (0·518-0·718) to 0·729 (0·643-0·941) for the PANGEA model (BM) and 0·670 (0·523-0·729) to 0·879 (0·586-0·938) for the PANGEA model (no BM). INTERPRETATION: Use of the PANGEA models in clinical practice will allow patients with precursor disease to receive more accurate measures of their risk of progression to multiple myeloma, thus prompting for more appropriate treatment strategies. FUNDING: SU2C Dream Team and Cancer Research UK.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Cowan A, Ferrari F, Freeman SS, et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 2023. PMID: 36858677. doi:10.1016/S2352-3026(22)00386-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。